Charles Bennett to Anemia
This is a "connection" page, showing publications Charles Bennett has written about Anemia.
Connection Strength
7.063
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.674
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.642
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.627
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.517
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.470
-
Is Intravenous Iron Supplementation Safe to Administer to Patients on Hemodialysis with Active Infection--What Do We Know, and What More Do We Need to Know? Clin J Am Soc Nephrol. 2015 Oct 07; 10(10):1714-5.
Score: 0.462
-
Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec; 18(4):421-9.
Score: 0.401
-
Forewarned is forearmed: erythropoietin use in CKD patients with cancer. J Nephrol. 2013 Sep-Oct; 26(5):805-6.
Score: 0.401
-
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med. 2010 Sep 13; 170(16):1490-8.
Score: 0.326
-
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar; 24(3):260-8.
Score: 0.314
-
Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009 Jan-Feb; 22(1):1-4.
Score: 0.288
-
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug; 48(8):1754-62.
Score: 0.277
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27; 299(8):914-24.
Score: 0.273
-
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. Cancer Treat Res. 2008; 140:235-51.
Score: 0.270
-
The blue cross blue shield assessment technology review: summary of findings. Best Pract Res Clin Haematol. 2005; 18(3):423-31.
Score: 0.219
-
Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Pract Res Clin Haematol. 2005; 18(3):449-54.
Score: 0.219
-
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. Expert Opin Drug Saf. 2016 Oct; 15(10):1421-6.
Score: 0.123
-
Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014 May 22; 370(21):2055-6.
Score: 0.105
-
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul; 6(6):536-64.
Score: 0.070
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 01; 111(1):25-41.
Score: 0.067
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
Score: 0.067
-
Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005 Apr 06; 97(7):489-98.
Score: 0.056
-
Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005; 18(3):467-72.
Score: 0.055
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
Score: 0.051
-
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct 01; 100(7):2303-20.
Score: 0.047
-
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010 Nov 18; 116(20):4045-59.
Score: 0.021
-
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010 Nov 20; 28(33):4996-5010.
Score: 0.021